


with an unrestricted grant by



FONDAZIONE
INTERNAZIONALE
MENARINI




CHRONIC LYMPHOCYTIC LEUKEMIA:

Advances in Pathogenesis and Treatment

Venice (Italy) - March 8th-10th, 2018

Hotel Monaco & Grand Canal
Sala del Ridotto





With an
unrestricted
grant by



FONDAZIONE
INTERNAZIONALE
MENARINI

Organized by



Centro di Riferimento Oncologico (CRO)
IRCCS Aviano

With the
patronage of



Università
degli Studi
di Udine



Università
degli Studi
di Trieste



Società Italiana
di Ematologia
(SIE)



Società Italiana
di Ematologia Sperimentale
(SIES)



Associazione Italiana
per la Ricerca
sul Cancro



International Society
Cellular Therapy

Director of
the Meeting

Valter GATTEI (Aviano, IT)

Scientific Program
Committee

Valter GATTEI (Aviano, IT)
Paolo DE PAOLI (Aviano, IT)

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in western world, and its incidence is significantly higher in elderly. Although in the past changes in the management of CLL patients occurred very slowly with few relevant findings in CLL biology, in the last 1-2 decades, we are witnessing an unprecedented burst of new discoveries that has rapidly transformed a relatively homogeneous and lethal disease into an unexpectedly heterogeneous one that can be often controlled for long periods thanks to an armamentarium of novel well-tolerated biologic drugs.

Given this scenario, a recapitulation of the several changes rapidly occurring in the fields of CLL pathogenesis, classification and risk stratification, as well as in the management of CLL patients has been though more than appropriate nowadays.

To do so, this meeting will encompass in the same context both “basic” topics (role of genetics, BCR and microenvironment interactions in CLL pathogenesis) and more “clinical” aspects (prognostic and predictive factors, role of chemo-immunotherapy and of target therapies, as well as of salvage therapies), all discussed by well-known CLL experts to provide an updated state-of-the-art on CLL useful for students, hematologists, practitioners and researchers.

Along with the Scientific Directorate of the Aviano Cancer Center, the meeting organizers and supporters, I look forward to welcoming you in Venice in March 2018.

President of the Meeting

Valter Gattei

*Clinical and Experimental Onco-Hematology Unit
Centro di Riferimento Oncologico, I.R.C.C.S.
Aviano, Italy*

Introduction



CHRONIC
LYMPHOCYTIC
LEUKEMIA:

Advances in
Pathogenesis
and Treatment

THURSDAY
March 8th
AFTERNOON

- 01.00 p.m.** Welcome lunch
- 02.00 p.m.** Introduction
V. GATTEI (Aviano, IT), P. DE PAOLI (Aviano, IT)
- 02.15 p.m.** Welcome to participants
A. CASINI (Florence, IT)

OPENING LECTURE

Chairperson: P. DE PAOLI (Aviano, IT)

- 02.30 p.m.** The role of microRNA in CLL pathogenesis
C. M. CROCE (Columbus, OH, US)

SESSION I MICROENVIRONMENTAL INTERACTIONS: THE ROLE OF BCR

*Chairpersons: T. N. HARTMANN (Salzburg, AT),
L. TRENTIN (Padua, IT)*

- 03.30 p.m.** BCR and CLL cell survival
F. FORCONI (Southampton, UK)
- 04.00 p.m.** The lesson of BCR structure
K. STAMATOPOULOS (Thessaloniki, GR)
- 04.30 p.m.** **Coffee break**
- 05.00 p.m.** BCR signaling: the lesson of murine models
D.G. EFREMOV (Trieste, IT)
- 05.30 p.m.** Antigen-independent BCR autonomous signaling
H. JUMAA (Ulm, DE)
- 06.00 p.m.** General discussion
End of day one

SESSION II MICROENVIRONMENTAL INTERACTIONS BEYOND BCR

Chairpersons: M. MASSAIA (Turin, IT), R. MARASCA (Modena, IT)

- 09.00 a.m.** The role of nurse-like cells
J. BURGER (Houston, TX, US)
- 09.30 a.m.** The role of the VLA-4 integrin
A. ZUCCHETTO (Aviano, IT)
- 10.00 a.m.** Mechanisms of immunosuppression in CLL
S. DEAGLIO (Turin, IT)
- Chairperson: V. GATTEI (Aviano, IT)*
- 10.30 a.m.** *Keynote Lecture:* The immune synapses in CLL
J. GRIBBEN (London, UK)

11.15 a.m. **Coffee break**

SESSION III THE GENETIC LANDSCAPE OF CLL

*Chairpersons: F. DI RAIMONDO (Catania, IT),
F. BERTONI (Bellinzona, CH)*

- 11.45 a.m.** Recurrent gene mutations in CLL
E. CAMPO (Barcelona, ES)
- 12.15 p.m.** NOTCH1 and SF3B1 mutations: physiopathology and clinical implications
D. ROSSI (Bellinzona, CH)
- 12.45 p.m.** Novel/rare mutations: physiopathology and clinical implications
R. ROSENQUIST (Uppsala, SW)
- 01.15 p.m.** **Buffet lunch**

FRIDAY
March 9th
MORNING

AFTERNOON



FRIDAY

March 9th

AFTERNOON

SESSION IV

PROGNOSTIC AND PREDICTIVE FACTORS IN CLL

Chairpersons: G. DEL POETA (Rome, IT), M. MONTILLO (Milan, IT)

02.15 p.m. Update on MBL: Biologic and Clinical Advances
N. KAY (Rochester, NY, US)

02.45 p.m. Novel and old prognosticators
G. GAIDANO (Novara, IT)

03.15 p.m. MRD as the new frontier of CLL management
P. GHIA (Milan, IT)

Chairperson: G. PIZZOLO (Verona, IT)

03.45 p.m. Keynote Lecture: The CLL ecosystem and what it means
for novel treatment approaches
F. CALIGARIS-CAPPIO (Milan, IT)

04.30 p.m. *Coffee break*

SESSION V

FROM CHEMO-IMMUNOTHERAPY TO TARGET THERAPIES

Chairpersons: G. POZZATO (Trieste, IT), L. LAURENTI (Rome, IT)

05.00 p.m. Chemo-immunotherapeutic approaches today
B. EICHHORST (Cologne, DE)

05.30 p.m. BTK/BCR inhibitors in CLL
A. WIESTNER (Bethesda, MD, US)

06.00 p.m. BLC-2 inhibitors in CLL
W. G. WIERDA (Houston, TX, US)

End of day two

SESSION VI

FROM TARGET THERAPIES TO SALVAGE THERAPIES

Chairpersons: M. SPINA (Aviano, IT), F. ZAJA (Udine, IT)

09.00 a.m. Comorbidities and other cancers in patients with CLL
A. FERRAJOLI (Houston, TX, US)

09.30 a.m. New mechanism-based drugs for all patients?
Still a role for chemo-immunotherapy?
R. FOA' (Rome, IT)

10.00 a.m. Discussion

10.15 a.m. *Coffee Break*

10.45 a.m. Allo-transplant in CLL
P. DREGER (Heidelberg, DE)

11.15 a.m. CAR-T in CLL
E. SHPALL (Houston, TX, US), K. REZVANI (Houston, TX, US)

11.45 a.m. Discussion

CLOSING LECTURE

Chairperson: V. GATTEI (Aviano, IT)

12.00 p.m. Advances on the molecular pathogenesis of CLL
R. DALLA FAVERA (New York, NY, US)

01.00 p.m. *Buffet Lunch*

SESSION VII

TAKE-HOME-MESSAGES AND FUTURE PERSPECTIVES

Chairpersons: G. GAIDANO (Novara, IT), D.G. EFREMOV (Trieste, IT)

02.00 p.m. BCR/microenvironment in CLL: future perspective
N. CHIORAZZI (Manhasset, NY, US)

02.30 p.m. Genetics in CLL: Future perspectives
C. WU (Boston, MA, US)

03.00 p.m. Clinical management of CLL: future perspective
E. MONTSERRAT (Barcelona, ES)

03.30 p.m. Closing remarks

04.30 p.m. CME Questionnaire

05.30 p.m. End of day three

SATURDAY

March 10th

MORNING

AFTERNOON



Meeting Venue

Hotel Monaco & Grand Canal

Sala del Ridotto
Piazza San Marco, 1332 - 30124 Venice

Official Language

The official language of the Congress will be English.
Simultaneous translation service will not be provided

Web Site

www.chroniclymphocyticleukemia-cro2018.com

Registration

The meeting is free to attend.
To Register online: www.targetmotivationpharma.com
inside of "Congress List"
To Register online: www.chroniclymphocyticleukemia-cro2018.com

**Continuing
Medical
Education (CME)**

Target Motivation s.r.l. is a CME provider-identification code n. 1346 and has assigned to the event no. 12,6 credits for Physicians, Biologists, X-ray Technicians, Cardiovascular Pathophysiology Technicians. Physicians for the following disciplines: Pathological Anatomy, Cardiac Surgery, Cardiology, Epidemiology, Medical Genetics, Internal Medicine, Radiodiagnostic, Geriatrics, Angio, Vascular Surgery, Emergency Care, Anaesthesia and Resuscitation, General Medicine

Please be aware that for the acquisition of credits is mandatory to have attended the 100% of the whole duration of the congress and selected at least the 75% of correct answers of the CME questionnaire

**Lunches and
Coffee Breaks**

Lunches and coffee breaks will be free of charge and served at the meeting venue.

**Certificates of
attendance**

Certificates of attendance will be issued at the registration desk following full attendance of the congress.

A Slide Center with PCs will be available for Speakers to preview and finalize their presentations. Speakers are kindly requested to submit their presentations on USB flash drive to the Slide Center technicians at least one hour before their talks.

The Secretariat and Slide Center will be open at the following times:
Thursday, March 8th, from 12.00 p.m. to 06.00. p.m.
Friday, March 9th, from 08.00 a.m. to 06.00. p.m.
Saturday, March 10th, from 08.00 a.m. to 05.30 p.m.



Via Circonvallazione 28 – 30171 Mestre (Venezia)
Tel. 041 2392670 – Fax 041 2392600
congress@targetmotivation.it
venezia2018@targetmotivation.it
www.targetmotivationpharma.com

**Technical
facilities**

**Secretariat and
Slide Center
during the Meeting**

**Organizing
Secretariat**



Faculty List

Francesco BERTONI

Institute of Oncology Research (IOR)
Fondazione per la Ricerca e la Cura dei Linfomi nel Ticino Lymphoma Unit
Oncology Institute of Southern Switzerland (IOSI)
Bellinzona, CH

Jan BURGER

Department of Leukemia Division of Cancer Medicine The University of Texas MD
Anderson Cancer Center
Houston, TX, US

Federico CALIGARIS-CAPPIO

Associazione Italiana per la Ricerca sul Cancro (AIRC)
Milan, IT

Elias CAMPO

Hematopathology Unit Hospital Clínic
Barcelona, ES

Nicholas CHIORAZZI

The Feinstein Institute for Medical Research
Manhasset, NY, US

Carlo M. CROCE

Department of Cancer Biology and Genetics the Ohio State University
Columbus, OH, US

Riccardo DALLA FAVERA

Institute for Cancer Genetics Columbia University
New York, NY, US

Paolo DE PAOLI

Centro di Riferimento Oncologico (CRO)
IRCCS
Aviano, IT

Silvia DEAGLIO

Medical Genetics University of Turin
School of Medicine & Italian Institute for Genomic Medicine
Turin, IT

Giovanni DEL POETA

Hematology DH Oncohematology University Tor Vergata
Rome, IT

Francesco DI RAIMONDO

Division of Hematology AOUP Vittorio Emanuele University of Catania
Catania, IT

Peter DREGER

Medical Clinic V University Clinic
Heidelberg, DE

Dimitar G.EFREMOV

Molecular Hematology Unit International Center for Genetic Engineering and
Biotechnology
Trieste, IT

Barbara EICHHORST

Division of Haematology Immunology Infectiology Intensive Care and Oncology University
of Cologne
Cologne, DE

Alessandra FERRAJOLI

Department of Leukemia, Division of Cancer Medicine The University of Texas MD
Anderson Cancer Center
Houston, TX, US

Robin FOA'

Division of Hematology University "Sapienza"
Rome, IT

Francesco FORCONI

Hematological Oncology Group, University of Southampton
Southampton, UK

Gianluca GAIDANO

Division of Haematology Department of Translational Medicine University of Eastern
Piedmont
Novara, IT

Valter GATTEI

Clinical and Experimental Onco-Hematology Unit Centro di Riferimento Oncologico (CRO)
IRCCS
Aviano, IT

Paolo GHIA

Department of Onco-Hematology University Vita-Salute San Raffaele
IRCCS Scientific Institute San Raffaele
Milan, IT

John GRIBBEN

Medical Oncology Barts Cancer Institute - a CR-UK Centre of Excellence Queen Mary
University of London
London, UK

Tanja N. HARTMANN

Third Medical Department, Paracelsus Medical University
Salzburg, AT

Faculty List



Faculty List

Hassan JUMAA

*Institute of Immunology University Hospital Ulm
Ulm, DE*

Neil KAY

*Department of Internal Medicine, Division of Hematology Mayo Clinic
Rochester, NY, US*

Luca LAURENTI

*UOC Ematologia Fondazione Policlinico Gemelli Università Cattolica del Sacro Cuore
Rome, IT*

Roberto MARASCA

*Department of Medical and Surgical Sciences, Section of Hematology University of
Modena and Reggio E. AOU Polyclinic
Modena, IT*

Massimo MASSAIA

*Department of Molecular Biotechnology and Health Science School of Medicine
University of Turin
Turin, IT*

Marco MONTILLO

*Department of Haematology & Oncology, Niguarda Cancer Center, Niguarda Hospital
Milan, IT*

Emili MONTSERRAT

*Department of Hematology Clinical Institute of Hemato-Oncological Diseases
Barcelona, ES*

Giovanni PIZZOLO

*University of Verona
Verona, IT*

Gabriele POZZATO

*Clinical Ematology Maggiore Hospital
Trieste, IT*

Katy REZVANI

*Cell Therapy Laboratory Department of Stem Cell Transplantation - Division of Cancer
Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, US*

Richard ROSENQUIST

*Department of Immunology, Genetics and Pathology Uppsala University
Uppsala, SE*

Davide ROSSI

*Hematology Service, Institute of Oncology of the Italian Switzerland (IOSI)
Lymphoma & Genomics Research Program Institute of Oncology Research (IOR)
Bellinzona, CH*

Elizabeth SHPALL

*Cell Therapy Laboratory Department of Stem Cell Transplantation - Division of Cancer
Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, US*

Michele SPINA

*Division of Medical Oncology, Centro di Riferimento Oncologico (CRO)
IRCCS
Aviano, IT*

Kostas STAMATOPOULOS

*Institute of applied Biosciences, Center for Research and Technology Hellas
Thessaloniki, GR*

Livio TRENTIN

*Hematology Division of Hematology, Department of Medicine University of Padua
Padua, IT*

William G. WIERDA

*Department of Leukemia, Division of Cancer Medicine The University of Texas MD
Anderson Cancer Center
Houston, TX, US*

Adrian WIESTNER

*Lymphoid Malignancies Section, Hematology Branch National Heart, Lung and Blood
Institute NHLBI - National
Institutes of Health NIH
Bethesda, MD, US*

Catherine WU

*Harvard Medical School
Dana-Farber Cancer Institute (DFCI)
Brigham and Women's Hospital
Boston, MA, IT*

Francesco ZAJA

*Division of Hematology Univeristy of Udine
Udine, IT*

Antonella ZUCCHETTO

*Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico
(CRO)
IRCCS
Aviano, IT*

Faculty List

Fondazione Internazionale Menarini
Symposia n. 378